Skip to main content

Table 3 Summary of antitumor activity of HQP1351 in the treatment of GIST xenografts in nude mice

From: Preclinical development of HQP1351, a multikinase inhibitor targeting a broad spectrum of mutant KIT kinases, for the treatment of imatinib-resistant gastrointestinal stromal tumors

Model

Drug

Schedules

Dose (mg/kg)

RTV

T/C (%)

GIST T1

Control

  

24.78 ± 2.51

 

HQP1351

q3d × 2w

20

13.93 ± 3.26**

56.2

40

7.21 ± 1.05**

29.1

qw × 3w

20

17.13 ± 2.19

69.1

40

13.47 ± 2.17**

54.4

Ponatinib

qw × 3w

40

16.10 ± 1.75*

65.0

GIST 430

Control

q3d × 3w

 

6.38 ± 0.74

 

HQP1351

q3d × 3w

10

3.58 ± 0.69**

56.1

50

2.39 ± 0.27**

37.5

Ponatinib

q3d × 3w

50

2.80 ± 0.42**

43.9

  1. RTV relative tumor volume, calculated by dividing the absolute tumor volume at the end of experiment with the absolute tumor volume at day 1
  2. *P < 0.05 vs. control; **P < 0.01 vs. control
Back to article page

Cell & Bioscience

ISSN: 2045-3701

Contact us